22 results match your criteria: "MEDALIS Drug Discovery Center[Affiliation]"
PLoS Pathog
May 2020
Department of Microbiology, The University of Alabama at Birmingham, Birmingham, Alabama, United States of America.
NAD, a key co-enzyme required for cell metabolism, is synthesized via two pathways in most organisms. Since schistosomes apparently lack enzymes required for de novo NAD biosynthesis, we evaluated whether these parasites, which infect >200 million people worldwide, maintain NAD homeostasis via the NAD salvage biosynthetic pathway. We found that intracellular NAD levels decline in schistosomes treated with drugs that block production of nicotinamide or nicotinamide mononucleotide-known NAD precursors in the non-deamidating salvage pathway.
View Article and Find Full Text PDFMedchemcomm
October 2019
Griffith Institute for Drug Discovery , Griffith University, Brisbane , Qld 4111 , Australia . Email: ; Tel: +61 7 3735 6006.
Currently, there is no established technique that allows the function of a compound produced by nature to be predicted by looking at its 2-dimensional chemical structure. One of chemistry's grand challenges: to find a function for every known metabolite. We explore the opportunity for Artificial Intelligence to provide rationale interrogation of metabolites to predict their function.
View Article and Find Full Text PDFSci Signal
May 2018
Institut National de la Santé et de la Recherche Médicale Unit 1108, Viral Pathogenesis Unit, Department of Virology, Institut Pasteur, 75015 Paris, France.
Biophysical methods and x-ray crystallography have revealed that class A G protein-coupled receptors (GPCRs) can form homodimers. We combined computational approaches with receptor cross-linking, energy transfer, and a newly developed functional export assay to characterize the residues involved in the dimerization interfaces of the chemokine receptor CCR5, the major co-receptor for HIV-1 entry into cells. We provide evidence of three distinct CCR5 dimeric organizations, involving residues of transmembrane helix 5.
View Article and Find Full Text PDFPlanta Med
March 2018
Laboratory of Therapeutic Innovation, Medalis Drug Discovery Center, University of Strasbourg, Illkirch, France.
Recently, we have demonstrated that site comparison methodology using flavonoid biosynthetic enzymes as the query could automatically identify structural features common to different flavonoid-binding proteins, allowing for the identification of flavonoid targets such as protein kinases. With the aim of further validating the hypothesis that biosynthetic enzymes and therapeutic targets can contain a similar natural product imprint, we collected a set of 159 crystallographic structures representing 38 natural product biosynthetic enzymes by searching the Protein Databank. Each enzyme structure was used as a query to screen a repository of approximately 10 000 ligandable sites by active site similarity.
View Article and Find Full Text PDFACS Chem Biol
July 2017
Laboratoire d'Innovation Thérapeutique, LIT UMR 7200 CNRS-Université de Strasbourg , MEDALIS Drug Discovery Center, Faculté de Pharmacie, 67400 Illkirch, France.
SmNACE is a NAD catabolizing enzyme expressed on the outer tegument of S. mansoni, a human parasite that is one of the major agents of the neglected tropical disease schistosomiasis. Recently, we identified aroylhydrazone derivatives capable of inhibiting the recombinant form of the enzyme with variable potency (IC ranging from 88 μM to 33 nM).
View Article and Find Full Text PDFFuture Med Chem
October 2016
UMR 7200 CNRS/Université de Strasbourg, MEDALIS Drug Discovery Center, 74 Route du Rhin, 67401, Illkirch, France.
Aim: We question the level of detail required in protein 3D-representation to detect site similarity which is relevant for polypharmacology prediction.
Results: We modified the in-house program SiteAlign to replace generic pharmacophoric descriptors of cavity-lining amino acids by descriptors accounting for solvent exposure. Benchmarking the novel, atom-based, method (SiteAlign2) revealed no global improvement of performance.
Eur J Med Chem
October 2015
Nanomedicine Lab, EA - 4662, UFR SMP 19 rue Ambroise Paré Université de Franche Comté, 25030 Besançon Cedex, France. Electronic address:
The development of inhibitors blocking STAT3 transcriptional activity is a promising therapeutic approach against cancer and inflammatory diseases. In this context, the selectivity of inhibitors against the STAT1 transcription factor is crucial as STAT3 and STAT1 play opposite roles in the apoptosis of tumor cells and polarization of the immune response. A structure-based virtual screening followed by a luciferase-containing promoter assay on STAT3 and STAT1 signaling were used to identify a selective STAT3 inhibitor.
View Article and Find Full Text PDFJ Med Chem
April 2015
‡Laboratoire d'Innovation Thérapeutique, MEDALIS Drug Discovery Center, Faculté de Pharmacie, LIT UMR7200 CNRS/Université de Strasbourg, 74 Route du Rhin, 67401 Illkirch, France.
The blood fluke Schistosoma mansoni is the causative agent of the intestinal form of schistosomiasis (or bilharzia). Emergence of Schistosoma mansoni with reduced sensitivity to praziquantel, the drug currently used to treat this neglected disease, has underlined the need for development of new strategies to control schistosomiasis. Our ability to screen drug libraries for antischistosomal compounds has been hampered by the lack of validated S.
View Article and Find Full Text PDFPlanta Med
April 2015
Laboratory of Therapeutic Innovation, Medalis Drug Discovery Center, Université de Strasbourg, Illkirch, France.
Natural products are made by nature through interaction with biosynthetic enzymes. They also exert their effect as drugs by interaction with proteins. To address the question "Do biosynthetic enzymes and therapeutic targets share common mechanisms for the molecular recognition of natural products?", we compared the active site of five flavonoid biosynthetic enzymes to 8077 ligandable binding sites in the Protein Data Bank using two three-dimensional-based methods (SiteAlign and Shaper).
View Article and Find Full Text PDFMed Sci (Paris)
December 2014
Institut de chimie organique et analytique (ICOA), UMR CNRS-université d'Orléans 7311, université d'Orléans, rue de Chartres, F-45067 Orléans Cedex 02, France.
A prerequisite to any virtual screening is the definition of compound libraries to be screened. As we describe here, various sources are available. The selection of the proper library is usually project-dependent but at least as important as the screening method itself.
View Article and Find Full Text PDFNucleic Acids Res
January 2015
Laboratoire d'innovation thérapeutique, Medalis Drug Discovery Center, UMR7200 CNRS-Université de Strasbourg, F-67400 Illkirch, France
The sc-PDB database (available at http://bioinfo-pharma.u-strasbg.fr/scPDB/) is a comprehensive and up-to-date selection of ligandable binding sites of the Protein Data Bank.
View Article and Find Full Text PDFJ Chem Inf Model
July 2014
Laboratory for Therapeutical Innovation, UMR 7200 Université de Strasbourg/CNRS, MEDALIS Drug Discovery Center, F-67400 Illkirch, France.
Bioisosteric replacement plays an important role in medicinal chemistry by keeping the biological activity of a molecule while changing either its core scaffold or substituents, thereby facilitating lead optimization and patenting. Bioisosteres are classically chosen in order to keep the main pharmacophoric moieties of the substructure to replace. However, notably when changing a scaffold, no attention is usually paid as whether all atoms of the reference scaffold are equally important for binding to the desired target.
View Article and Find Full Text PDFMol Inform
June 2014
Laboratoire de Chémoinformatique, UMR 7140 CNRS/Université de Strasbourg, 1 rue Blaise Pascal, F-67000 Strasbourg, France.
Biochim Biophys Acta
July 2014
Laboratoire de Conception et Application de Molécules Bioactives, UMR 7199 CNRS-Université de Strasbourg, Faculté de Pharmacie, Medalis Drug Discovery Center, 74 route du Rhin, 67400 Illkirch, France.
Bovine CD38/NAD(+) glycohydrolase catalyzes the hydrolysis of NAD(+) to nicotinamide and ADP-ribose and the formation of cyclic ADP-ribose via a stepwise reaction mechanism. Our recent crystallographic study of its Michaelis complex and covalently-trapped intermediates provided insights into the modalities of substrate binding and the molecular mechanism of bCD38. The aim of the present work was to determine the precise role of key conserved active site residues (Trp118, Glu138, Asp147, Trp181 and Glu218) by focusing mainly on the cleavage of the nicotinamide-ribosyl bond.
View Article and Find Full Text PDFTrends Pharmacol Sci
May 2014
Laboratoire d'Innovation Thérapeutique, UMR 7200, MEDALIS Drug Discovery Center, 74 route du Rhin, 67400 Illkirch, France.
Mol Inform
December 2013
UMR 7200 CNRS-Université de Strasbourg, MEDALIS Drug Discovery Center, 74 route du Rhin, 67400, Illkirch, France.
Biochim Biophys Acta
December 2013
Laboratoire de Conception et Application de Molécules Bioactives, UMR 7199 CNRS-Université de Strasbourg, Faculté de Pharmacie, Medalis Drug Discovery Center, 74 route du Rhin, 67400 Illkirch, France.
Schistosoma mansoni NAD(+) catabolizing enzyme (SmNACE), a distant homolog of mammalian CD38, shows significant structural and functional analogy to the members of the CD38/ADP-ribosyl cyclase family. The hallmark of SmNACE is the lack of ADP-ribosyl cyclase activity that might be ascribed to subtle changes in its active site. To better characterize the residues of the active site we determined the kinetic parameters of nine mutants encompassing three acidic residues: (i) the putative catalytic residue Glu202 and (ii) two acidic residues within the 'signature' region (the conserved Glu124 and the downstream Asp133), (iii) Ser169, a strictly conserved polar residue and (iv) two aromatic residues (His103 and Trp165).
View Article and Find Full Text PDFJ Chem Inf Model
September 2013
Laboratory for Therapeutical Innovation, UMR 7200 Université de Strasbourg/CNRS, MEDALIS Drug Discovery Center, F-67400 Illkirch, France.
Computational target fishing is a chemoinformatic method aimed at determining main and secondary targets of bioactive compounds in order to explain their mechanism of action, anticipate potential side effects, or repurpose existing drugs for novel therapeutic indications. Many existing successes in this area have been based on a use of a single computational method to estimate potentially new target-ligand associations. We herewith present an automated workflow using several methods to optimally browse target-ligand space according to existing knowledge on either ligand and target space under investigation.
View Article and Find Full Text PDFJ Chem Inf Model
March 2013
Laboratory for Therapeutical Innovation, UMR 7200 Université de Strabsourg/CNRS , MEDALIS Drug Discovery Center, F-67400 Illkirch, France.
We herewith present a novel and universal method to convert protein-ligand coordinates into a simple fingerprint of 210 integers registering the corresponding molecular interaction pattern. Each interaction (hydrophobic, aromatic, hydrogen bond, ionic bond, metal complexation) is detected on the fly and physically described by a pseudoatom centered either on the interacting ligand atom, the interacting protein atom, or the geometric center of both interacting atoms. Counting all possible triplets of interaction pseudoatoms within six distance ranges, and pruning the full integer vector to keep the most frequent triplets enables the definition of a simple (210 integers) and coordinate frame-invariant interaction pattern descriptor (TIFP) that can be applied to compare any pair of protein-ligand complexes.
View Article and Find Full Text PDFVirologie (Montrouge)
February 2013
Université de Strasbourg, faculté de pharmacie, UMR7200/MEDALIS Drug Discovery Center, 74, route du Rhin, 67401 Illkirch, France.
J Chem Inf Model
September 2012
UMR 7200 CNRS/Université de Strasbourg, MEDALIS Drug Discovery Center, 74 Route du Rhin, 67401 Illkirch, France.
Selectivity is a key factor in drug development. In this paper, we questioned the Protein Data Bank to better understand the reasons for the promiscuity of bioactive compounds. We assembled a data set of >1000 pairs of three-dimensional structures of complexes between a "drug-like" ligand (as its physicochemical properties overlap that of approved drugs) and two distinct "druggable" protein targets (as their binding sites are likely to accommodate "drug-like" ligands).
View Article and Find Full Text PDFJ Chem Inf Model
August 2012
Laboratory of Therapeutic Innovation, UMR 7200 Université de Strasbourg/CNRS, Medalis Drug Discovery Center, F-67400 Illkirch, France.
Estimating the pairwise similarity of protein-ligand binding sites is a fast and efficient way of predicting cross-reactivity and putative side effects of drug candidates. Among the many tools available, three-dimensional (3D) alignment-dependent methods are usually slow and based on simplified representations of binding site atoms or surfaces. On the other hand, fast and efficient alignment-free methods have recently been described but suffer from a lack of interpretability.
View Article and Find Full Text PDF